Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

Journal of Clinical Oncology

Volumn 18, Issue 1, 2000, Pages 158-166

  Middleton, M R ^a   Grob, J J ^a   Aaronson, N ^a   Fierlbeck, G ^a   Tilgen, W ^a   Seiter, S ^a   Gore, M ^a   Aamdal, S ^a   Cebon, J ^a   Coates, A ^a   Dreno, B ^a   Henz, M ^a   Schadendorf, D ^a   Kapp, A ^a   Weiss, J ^a   Fraass, U ^a   Statkevich, P ^a   Muller, M ^a   Thatcher, N ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; TEMOZOLOMIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

EID: 0033989205     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.1.158     Document Type: Article

References (31)

1. Coleman MP, Esteve J, Damiecki P, et al: Trends in Cancer Incidence and Mortality. Lyons, France, IARC, Scientific Publication no. 121, 1993
2. Lee SM, Betticher DC, Thatcher N: Melanoma: Chemotherapy. Br Med Bull 51:609-630, 1995
3. Balch CM, Reintgen DS, Kirkwood JM, et al: Cutaneous melanoma, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 1947-1994
4. Middleton MR, Lorigan P, Owen J, et al: Dacarbazine, BCNU, cisplatin and tamoxifen (DBCT) v dacarbazine and interferon (D/I) in advanced melanoma: Interim results of a randomized phase III study. Proc Am Soc Clin Oncol 17:508a, 1998 (abstr 1958)
5. Legha S: The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol 24:S24-S31, 1997 (suppl 4)
6. Barth A, Wanek LA, Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181:193-201, 1995
7. Dreiling L, Hoffman S, Robinson WA: Melanoma: Epidemiology, pathogenesis, and new modes of treatment. Adv Intern Med 41:553-604, 1996
8. Stevens MFG, Hickman JA, Langdon SP, et al: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47:5846-5852, 1987
9. 6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU cytotoxicity in human tumour cells. Br J Cancer 67:1299-1302, 1993
10. 6-alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukaemic patients. Ann Oncol 6:389-393, 1995
11. 6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 36:457-462, 1987
12. 6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 74:1030-1036, 1996
13. Newlands ES, Blackledge GRP, Slack JA, et al: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65:287-291, 1992
14. Agarwala SS, Reyderman L, Statkevich P: Pharmacokinetic study of temozolomide penetration into CSF in a patient with durai melanoma. Ann Oncol 9:138 (abstr 659)
15. Patel M, McCully C, Godwin K, et al: Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc Am Soc Clin Oncol 14:461, 1995 (abstr 1485)
16. 11C-temozolomide uptake by human recurrent high grade astrocytomas. Br J Cancer 75:1241, 1997 (abstr)
17. O'Reilly SM, Newlands ES, Glaser MG, et al: Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A:940-942, 1993
18. Newlands ES, O'Reilly SM, Glaser MG, et al: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A:2236-2241, 1996
19. Bower M, Newlands ES, Bleehen NM, et al: Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40:484-488, 1997
20. Bleehen NM, Newlands ES, Lee SM, et al: Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13:910-913, 1995
21. National Cancer Institute: Investigator's Handbook: A Manual for Participants in Clinical Trials of Investigational Agents Sponsored by DCTD, NCI. Bethesda, MD, National Cancer Institute, 1993
22. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO publication no. 48. Geneva, Switzerland, World Health Organization, 1979
23. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
24. Estlin EJ, Lashford L, Ablett S: Phase I study of temozolomide in paediatric patients with advanced cancer. Br J Cancer 78:652-666, 1988
25. Kim LH, Lin CC, Parker D. et al: High-performance liquid Chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temolozolomide, in human plasma. J Chromatogr B Biomed Sci Appl 703:225-233, 1997
26. Pyrhönen S, Hahka-Kemppinen M, Muhonen T: A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 10:1919-1926, 1992
27. 6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 78:1199-1202, 1998
28. Brock CS, Newlands ES, Wedge SR, et al: Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 38:4363-4367, 1998
29. Margison GP, O'Connor PJ: Biological consequences of reactions with DNA: Role of specific lesions, in Cooper C, Groves P (eds): Handbook of Experimental Pharmacology. Berlin, Germany, Springer-Verlag, 1990, pp 547-566
30. 6-alkylguanine DNA alkyltransferase with twice daily oral temozolomide (SCH 52365) in patients with advanced cancer. Proc Am Soc Clin Oncol 15:178, 1996 (abstr 366)
31. Kirkwood JM, Agarwala SS, Diaz B, et al: Phase I study of temozolomide in combination with interferon alfa-2b in metastatic malignant melanoma. Proc Am Soc Clin Oncol 16:491a, 1997 (abstr 1767)